BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 38063931)

  • 1. Moving beyond cisplatin resistance: mechanisms, challenges, and prospects for overcoming recurrence in clinical cancer therapy.
    Fu R; Zhao B; Chen M; Fu X; Zhang Q; Cui Y; Hu X; Zhou W
    Med Oncol; 2023 Dec; 41(1):9. PubMed ID: 38063931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New advances into cisplatin resistance in head and neck squamous carcinoma: Mechanisms and therapeutic aspects.
    Hu H; Li B; Wang J; Tan Y; Xu M; Xu W; Lu H
    Biomed Pharmacother; 2023 Jul; 163():114778. PubMed ID: 37137185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of cisplatin resistance in bladder cancer by epigenetic mechanisms.
    Li F; Zheng Z; Chen W; Li D; Zhang H; Zhu Y; Mo Q; Zhao X; Fan Q; Deng F; Han C; Tan W
    Drug Resist Updat; 2023 May; 68():100938. PubMed ID: 36774746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting ferroptosis in ovarian cancer: Novel strategies to overcome chemotherapy resistance.
    Kapper C; Oppelt P; Arbeithuber B; Gyunesh AA; Vilusic I; Stelzl P; Rezk-Füreder M
    Life Sci; 2024 Jul; 349():122720. PubMed ID: 38762066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autophagy-driven regulation of cisplatin response in human cancers: Exploring molecular and cell death dynamics.
    Yang Y; Liu L; Tian Y; Gu M; Wang Y; Ashrafizadeh M; Reza Aref A; Cañadas I; Klionsky DJ; Goel A; Reiter RJ; Wang Y; Tambuwala M; Zou J
    Cancer Lett; 2024 Apr; 587():216659. PubMed ID: 38367897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting DNA Damage Response and Repair to Enhance Therapeutic Index in Cisplatin-Based Cancer Treatment.
    Kiss RC; Xia F; Acklin S
    Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of Cisplatin Resistance in HPV Negative Head and Neck Squamous Cell Carcinomas.
    Griso AB; Acero-Riaguas L; Castelo B; Cebrián-Carretero JL; Sastre-Perona A
    Cells; 2022 Feb; 11(3):. PubMed ID: 35159370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes.
    Shen DW; Pouliot LM; Hall MD; Gottesman MM
    Pharmacol Rev; 2012 Jul; 64(3):706-21. PubMed ID: 22659329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overcoming resistance to cisplatin by inhibition of glutathione S-transferases (GSTs) with ethacraplatin micelles in vitro and in vivo.
    Li S; Li C; Jin S; Liu J; Xue X; Eltahan AS; Sun J; Tan J; Dong J; Liang XJ
    Biomaterials; 2017 Nov; 144():119-129. PubMed ID: 28834763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New Insights into Mechanisms of Cisplatin Resistance: From Tumor Cell to Microenvironment.
    Chen SH; Chang JY
    Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31450627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Role of mTORC1 Pathway and Autophagy in Resistance to Platinum-Based Chemotherapeutics.
    Pan Z; Zhang H; Dokudovskaya S
    Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cisplatin and beyond: molecular mechanisms of action and drug resistance development in cancer chemotherapy.
    Makovec T
    Radiol Oncol; 2019 Mar; 53(2):148-158. PubMed ID: 30956230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular mechanisms of platinum‑based chemotherapy resistance in ovarian cancer (Review).
    Yang L; Xie HJ; Li YY; Wang X; Liu XX; Mai J
    Oncol Rep; 2022 Apr; 47(4):. PubMed ID: 35211759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Corrosion-Activated Chemotherapeutic Function of Nanoparticulate Platinum as a Cisplatin Resistance-Overcoming Prodrug with Limited Autophagy Induction.
    Cheng HJ; Wu TH; Chien CT; Tu HW; Cha TS; Lin SY
    Small; 2016 Nov; 12(44):6124-6133. PubMed ID: 27717137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circumvention of cisplatin resistance in ovarian cancer by combination of cyclosporin A and low-intensity ultrasound.
    Yu T; Yang Y; Zhang J; He H; Ren X
    Eur J Pharm Biopharm; 2015 Apr; 91():103-10. PubMed ID: 25668779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A platinum(II) complex HY1-Pt overcomes cisplatin-induced resistance and attenuates metastasis of epithelial ovarian cancer by cancer cell stemness inhibition.
    Wang X; Wang Y; Gou S
    Int J Biochem Cell Biol; 2023 Apr; 157():106395. PubMed ID: 36871936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA Methylation of miR-7 is a Mechanism Involved in Platinum Response through
    Vera O; Jimenez J; Pernia O; Rodriguez-Antolin C; Rodriguez C; Sanchez Cabo F; Soto J; Rosas R; Lopez-Magallon S; Esteban Rodriguez I; Dopazo A; Rojo F; Belda C; Alvarez R; Valentin J; Benitez J; Perona R; De Castro J; Ibanez de Caceres I
    Theranostics; 2017; 7(17):4118-4134. PubMed ID: 29158814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long noncoding RNAs as biotargets in cisplatin-based drug resistance.
    Abu N; Hon KW; Jeyaraman S; Jamal R
    Future Oncol; 2018 Dec; 14(29):3085-3095. PubMed ID: 30468082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Research Progress of DNA Methylation in Cisplatin Resistance in Lung Cancer].
    Sun J; Chen J
    Zhongguo Fei Ai Za Zhi; 2023 Jan; 26(1):52-58. PubMed ID: 36792081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overcome of Cisplatin Resistance in Ovarian Cancer by Combination of Low-intensity Ultrasound and Cisplatin.
    Kip B; Aydin O
    Curr Drug Deliv; 2023; 20(9):1380-1390. PubMed ID: 35761504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.